Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United ...

The film “Lilly,” a biopic about the equal pay icon Lilly Ledbetter, lands in theaters at a difficult time for her biggest ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9< ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron. Web editor Nicole Raleigh speaks with Rob Abbott ...